



**SUPPLEMENTARY FIG. S5.** NRTI screening and efficacy and toxicity of tenofovir. **(a)** Efficacy of the indicated NRTI at the indicated reference concentrations to inhibit VSV-G pseudotyped LV integration in RD2-MolPack-*Chim3* cells. **(b)** Efficacy of different concentrations of tenofovir in inhibiting three distinct MOI of LV to transduce RD2-MolPack-*Chim3* cells. **(c)** Viability and **(d)** cell counts of RD2-MolPack-*Chim3* cells transduced at different MOI of LV either in the presence or in the absence of three concentrations of tenofovir. MOI, multiplicity of infection.